An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia
Open Access
- 22 January 2015
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (4) , e995568
Abstract
Many acute leukemia patients treated with chemotherapy are at high risk of relapse without allogeneic stem cell transplantation, an immunotherapy that is limited by significant toxicity and donor availability. We propose that post-remission vaccination with a simple autologous whole cell vaccine adjuvanted with α-galactosylceramide may be effective to prevent relapse of acute leukemia.Keywords
This publication has 10 references indexed in Scilit:
- An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatmentBlood, 2014
- Acute myeloid leukemia: 2014 Update on risk‐stratification and managementAmerican Journal of Hematology, 2014
- Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL geneBritish Journal of Haematology, 2014
- Immunotherapy in Acute Myeloid LeukemiaImmunotherapy, 2013
- Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for ImmunotherapyClinical Cancer Research, 2013
- Immunotherapeutic strategies for relapse control in acute myeloid leukemiaBlood Reviews, 2013
- Acute lymphoblastic leukaemiaThe Lancet, 2013
- Immunologic Consequences of Chemotherapy for Acute Myeloid LeukemiaJournal of Pediatric Hematology/Oncology, 2013
- Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapyHaematologica, 2012
- Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?Blood, 2011